Ovid Therapeutics (OVID) Stock Forecast & Price Target

Ovid Therapeutics is attractive because its lead asset OV329 targets a clinically validated epilepsy mechanism, yet is engineered to avoid vigabatrin’s retinal toxicity, which has historically capped uptake despite efficacy; the company has already shown clean ophthalmic findings in 68 healthy volunteers and cortical inhibition exceeding vigabatrin’s signal at 400-600x lower dose. Its opportunity is reinforced by large unmet need, with 30-40% of the ~3M U.S. epilepsy population still experiencing recurrent seizures and orphan pediatric indications like TSC and infantile spasms offering premium pricing and over $700M in combined peak worldwide revenue potential. The balance sheet also supports execution, with $169.8M in cash and marketable securities as of June 30, 2026 funding operations into 2029, while upcoming PPR, TSC, and OV4071 readouts could further de-risk the pipeline and unlock multiple value drivers.

Ovid Therapeutics is viewed negatively because its core epilepsy pipeline faces substantial clinical and regulatory risk, including vigabatrin-class ocular toxicity, trial failure, unexpected safety signals, and delays that could erase program value. The bear case assumes only a 20% probability of success across all three indications, and under a 12% discount rate the $0.58 bear value is supported by FY27 net cash and exercise proceeds alone, implying the KCC2 pipeline (OV4071) is effectively worthless. With potential step-therapy positioning, new competitors, and financing risk until cash flow positive, the company looks more like a cash shell than a durable growth story.